51-09-2

Usage

Uses

Synthesis of organic compounds and pharmaceuticals It serves as an intermediate in the production of various complex molecules.

Derivative of pyrrole

Heterocyclic aromatic organic compound It is based on the pyrrole structure, which is a five-membered ring with one nitrogen atom.

Applications

Dyes, pigments, pharmaceuticals, and agrochemicals The compound is used as a building block in the production of various commercial products.

Physical appearance

Dark red to brown crystalline solid The compound forms solid crystals with a characteristic color.

Molecular weight

216.33 g/mol The total mass of one mole of the compound.

Melting point

49-50 °C The temperature range at which the compound transitions from a solid to a liquid state.

Hazardous material

Requires proper handling and storage The chemical is considered hazardous, and safety precautions must be taken to minimize risks.

Upstream product

• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 
• 94-09-7 p-aminoethylbenzoate 
• 3948-64-9 N-(2-morpholinoethyl)-4-nitrobenzamide 
• 122-04-3 4-nitro-benzoyl chloride 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 619-45-4 4-methoxycarbonyl aniline 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 1033776-87-2 4-[2-hydroxy-2-(4-trifluoromethylphenyl)acetylamino]-N-(2-morpholin-4-ylethyl)benzamide 
• 1229653-18-2 C₂₄H₃₄N₄O₃ 
• 1229653-21-7 C₂₀H₂₃ClN₄O₃ 
• 1229653-19-3 C₂₀H₂₄N₄O₃ 
• 1229653-20-6 C₂₀H₂₃FN₄O₃ 
• 1229653-17-1 C₂₀H₃₀N₄O₃ 
• 1229653-22-8 C₂₁H₂₃F₃N₄O₃ 
• 701301-43-1 N-(2-morpholin-4-yl-ethyl)-4-[3-(4-trifluoromethoxy-phenyl)-ureido]-benzamide 
• 700806-10-6 4-(5-amino-1-pyridin-2-yl-1H-[1,2,4]triazol-3-ylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF

The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

Comparative study of dG affinity vs. DNA methylation modulating properties of side chain derivatives of procainamide: Insight into its DNA hypomethylating effect

Procainamide derivatives have been synthesized to investigate the role of side chains in modulating the DNA methylation level in cancer cells and gain insight into its mechanism of action. The synthesized derivatives comprised of flexible (dimethyl), cons

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF

Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.

Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase

The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N′-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment.

NOVEL CARBOXAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS

Novel compounds of formula (I) which modulate MCH activity are disclosed, in which A is a linker; B is a connecting moiety; Ar1 and Ar2 are aryl or heteroaryl groups; R1 and R2 are hydrogen, halogen atoms, CF3, OCF3/